JPWO2020202831A1 - - Google Patents

Info

Publication number
JPWO2020202831A1
JPWO2020202831A1 JP2021511185A JP2021511185A JPWO2020202831A1 JP WO2020202831 A1 JPWO2020202831 A1 JP WO2020202831A1 JP 2021511185 A JP2021511185 A JP 2021511185A JP 2021511185 A JP2021511185 A JP 2021511185A JP WO2020202831 A1 JPWO2020202831 A1 JP WO2020202831A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021511185A
Other languages
Japanese (ja)
Other versions
JP7576334B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2020202831A1 publication Critical patent/JPWO2020202831A1/ja
Application granted granted Critical
Publication of JP7576334B2 publication Critical patent/JP7576334B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021511185A 2019-03-29 2020-02-14 放射性医薬の製造方法及び放射性医薬 Active JP7576334B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019068873 2019-03-29
JP2019068873 2019-03-29
PCT/JP2020/005830 WO2020202831A1 (ja) 2019-03-29 2020-02-14 放射性医薬の製造方法及び放射性医薬

Publications (2)

Publication Number Publication Date
JPWO2020202831A1 true JPWO2020202831A1 (https=) 2020-10-08
JP7576334B2 JP7576334B2 (ja) 2024-10-31

Family

ID=72667952

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021511185A Active JP7576334B2 (ja) 2019-03-29 2020-02-14 放射性医薬の製造方法及び放射性医薬

Country Status (4)

Country Link
US (1) US20220175973A1 (https=)
JP (1) JP7576334B2 (https=)
CN (1) CN113766952B (https=)
WO (1) WO2020202831A1 (https=)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008709A1 (fr) * 1997-08-14 1999-02-25 Daiichi Radioisotope Laboratories, Ltd. Medicament radioactif stable
JP2006528644A (ja) * 2003-07-24 2006-12-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
WO2009141965A1 (ja) * 2008-05-22 2009-11-26 旭化成メディカル株式会社 濾過方法
JP2012514007A (ja) * 2008-12-31 2012-06-21 アビド・ラジオファーマシューティカルス・インコーポレイテッド トシラート前駆体からの１８ｆ−放射性標識スチリルピリジンおよびその安定性医薬組成物の合成
JP2012524064A (ja) * 2009-04-15 2012-10-11 ランセウス メディカル イメージング， インコーポレイテッド アスコルビン酸による放射性医薬組成物の安定化
JP2014129316A (ja) * 2012-12-27 2014-07-10 Nihon Medi Physics Co Ltd 放射性医薬及び医薬キット
JP2015081242A (ja) * 2013-10-23 2015-04-27 日本メジフィジックス株式会社 放射性医薬組成物の製造方法
JP2015516457A (ja) * 2012-05-18 2015-06-11 エム・ウント・カー・メディカル・インヴェント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＭ ＆ Ｋ Ｍｅｄｉｃａｌ Ｉｎｖｅｎｔ Ｇｍｂｈ 放射性医薬品の製造用キット及び製造方法
JP2016515517A (ja) * 2013-03-15 2016-05-30 オークウッド ラボラトリーズ，エル．エル．シー． 徐放性ミクロスフェア及びその製造方法
JP2016528233A (ja) * 2013-08-08 2016-09-15 シーエスエル、リミテッド 混入物除去方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056205A2 (en) * 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
US20100196272A1 (en) * 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
AR079687A1 (es) * 2009-12-23 2012-02-15 Bayer Schering Pharma Ag Formulaciones adecuadas para el diagnostico por imagenes con pet
WO2011147762A2 (en) * 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
WO2013173004A2 (en) * 2012-04-10 2013-11-21 Lantheus Medical Imaging, Inc. Radiopharmaceutical synthesis methods
JP6472493B2 (ja) * 2017-08-01 2019-02-20 日本メジフィジックス株式会社 放射性医薬組成物

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008709A1 (fr) * 1997-08-14 1999-02-25 Daiichi Radioisotope Laboratories, Ltd. Medicament radioactif stable
JP2006528644A (ja) * 2003-07-24 2006-12-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
WO2009141965A1 (ja) * 2008-05-22 2009-11-26 旭化成メディカル株式会社 濾過方法
JP2012514007A (ja) * 2008-12-31 2012-06-21 アビド・ラジオファーマシューティカルス・インコーポレイテッド トシラート前駆体からの１８ｆ−放射性標識スチリルピリジンおよびその安定性医薬組成物の合成
JP2012524064A (ja) * 2009-04-15 2012-10-11 ランセウス メディカル イメージング， インコーポレイテッド アスコルビン酸による放射性医薬組成物の安定化
JP2015516457A (ja) * 2012-05-18 2015-06-11 エム・ウント・カー・メディカル・インヴェント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＭ ＆ Ｋ Ｍｅｄｉｃａｌ Ｉｎｖｅｎｔ Ｇｍｂｈ 放射性医薬品の製造用キット及び製造方法
JP2014129316A (ja) * 2012-12-27 2014-07-10 Nihon Medi Physics Co Ltd 放射性医薬及び医薬キット
JP2016515517A (ja) * 2013-03-15 2016-05-30 オークウッド ラボラトリーズ，エル．エル．シー． 徐放性ミクロスフェア及びその製造方法
JP2016528233A (ja) * 2013-08-08 2016-09-15 シーエスエル、リミテッド 混入物除去方法
JP2015081242A (ja) * 2013-10-23 2015-04-27 日本メジフィジックス株式会社 放射性医薬組成物の製造方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN, JIANQING ET AL.: "Synthsis, stabilization and formulation of [177Lu]Lu-AMBA, a systemic radiotherapeutic agent for gas", APPL RADIAT ISOT, vol. 66, JPN6020013970, 2008, pages 497 - 505, ISSN: 0005309405 *
MOHSIN, FARHEEN ET AL.: "Comparison of stabilizers, myo-inositol and D-mannitol for 99mTc-DMSA(III)", J CHEM SOC PAK, vol. 30, no. 6, JPN6020013971, 2008, pages 907 - 912, ISSN: 0005309406 *
SCOTT, PETER, J. H. ET AL.: "Studies into radiolytic decomposition of fluorine-18 labeled radiopharmaceuticals for positron emiss", APPL RADIAT ISOT, vol. 67, no. 1, JPN6020013969, 2009, pages 88 - 94, ISSN: 0005309404 *
TAKAAT, H. M. ET AL.: "Synthesis of 99mTc-radiolabeled uridine as a potential tumor imaging agent", RADIOCHEMISTRY, vol. 60, no. 1, JPN6020013972, 2018, pages 51 - 57, ISSN: 0005309407 *

Also Published As

Publication number Publication date
CN113766952A (zh) 2021-12-07
WO2020202831A1 (ja) 2020-10-08
JP7576334B2 (ja) 2024-10-31
US20220175973A1 (en) 2022-06-09
CN113766952B (zh) 2023-09-08

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021012348A2 (https=)
BR112021018250A2 (https=)
BR112021018584A2 (https=)
BR112021017310A2 (https=)
BR112021018484A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210927

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20211117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241011

R150 Certificate of patent or registration of utility model

Ref document number: 7576334

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150